Tagrisso 80mg (Osimertinib) – 30 Tablets pack

$3,700.00

Buy Tagrisso 80mg Online Without Prescription. Order Tagrisso 80mg tablets Online. Purchase Tagrisso 80mg Online.

Tagrisso 80mg (Osimertinib) is a targeted therapy that is used to treat some non-small cell lung cancers (NSCLC) that have a certain EGFR (epidermal growth factor receptor) mutation, specifically exon 19 deletions or exon 21 mutations.

Compare

Description

Tagrisso 80mg (Osimertinib) is a targeted therapy that is used to treat some non-small cell lung cancers (NSCLC) that have a certain EGFR (epidermal growth factor receptor) mutation, specifically exon 19 deletions or exon 21 mutations.

DOSAGE & INDICATIONS

For the treatment of metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
For the first-line treatment of metastatic EGFR (exon 19 deletion or exon 21 (L858R) substitution) mutation-positive non-small cell lung cancer (NSCLC).
NOTE: Confirm the presence of a EGFR exon 19 deletion or exon 21 (L858R) substitution mutation in tumor specimens prior to initiation of treatment with osimertinib.
Oral dosage
Adults

Tagrisso 80mg (Osimertinib) by mouth once daily, until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized, double-blind clinical trial of previously untreated patients with metastatic EGFR (exon 19 deletion or exon 21 (L858R) substitution) mutation-positive NSCLC, treatment with osimertinib significantly improved median progression-free survival (PFS) compared with an EGFR tyrosine kinase inhibitor (TKI) (e.g., gefitinib or erlotinib) (18.9 months vs. 10.2 months). The overall response rate was 77% (complete response (CR), 2%) with a median duration of 17.6 months in the osimertinib arm compared with 69% (CR, 1%) and a median duration of 9.6 months in the EGFR TKI arm. Overall survival data were not yet mature.

For the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), after progression on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
NOTE: Confirm the presence of a T790M EGFR mutation in tumor specimens prior to initiation of treatment with osimertinib. If a tumor biopsy cannot be obtained, test for the T790M EGFR mutation in plasma specimens; however, if not detected in a plasma specimen, re-evaluate the feasibility of biopsy for tumor tissue testing.
Oral dosage
Adults

80 mg by mouth once daily, until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, open-label, phase 3 clinical trial (AURA3), patients with T790M-positive advanced NSCLC with disease progression after first-line EGFR-TKI therapy, treatment with osimertinib significantly improved median progression-free survival (PFS) compared with pemetrexed plus carboplatin or cisplatin (10.1 vs. 4.4 months); the benefit of osimertinib on PFS was consistent among patients with CNS metastases (8.5 vs. 4.2 months). The overall response rate (ORR) was also significantly better for patient who received osimertinib compared with pemetrexed plus platinum therapy (65% vs. 29%), with a median duration of 11 months versus 4.2 months, respectively. The ORR for patients with CNS tumors was 57% (complete response (CR), 7%) in patients treated with osimertinib compared with 25% (CR, 0%) in patients who received chemotherapy, with 57% of osimertinib patients maintaining a CNS response of greater than or equal to 6 months and 12% maintaining a response of 9 months or longer; no patients treated with chemotherapy maintained a response longer than 6 months. Data for overall survival were not yet mature.

ADMINISTRATION Tagrisso 80mg

Oral Administration
Oral Solid Formulations

Take with or without food.
If a dose is missed, do not make up the missed dose. Take the next dose as scheduled.

Extemporaneous Compounding-Oral

For oral administration in patients who have difficulty swallowing solids:
Disperse tablet in 2 ounces (approximately 60 mL) of non-carbonated water; do not mix with other liquids.
Stir until tablet is dispersed into small pieces; it will not completely dissolve. Do not crush, heat, or ultrasonicate during preparation.
Swallow immediately.
Rinse the container with 4 to 8 ounces (120 mL to 240 mL) of water and immediately drink.
For nasogastric (NG) tube administration:
Disperse tablet in 15 mL of non-carbonated water; do not mix with other liquids.
Stir until tablet is dispersed into small pieces; it will not completely dissolve. Do not crush, heat, or ultrasonicate during preparation.
Use an additional 15 mL of water to transfer any residues to the syringe.
Administer this 30 mL as per NG tube instructions with appropriate water flushes (approximately 30 mL).

STORAGE Tagrisso 80mg

Tagrisso:
– Store at 77 degrees F; excursions permitted to 59-86 degrees F

MECHANISM ACTION OF Tagrisso 80mg

Tagrisso 80mg (Osimertinib) is a kinase inhibitor of the epidermal growth factor receptor (EGFR), irreversibly binding to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at concentrations that are approximately 9-fold lower than for wild-type EGFR. In cultured cells and animal models, it has shown NSCLC anti-tumor activity against the following EGFR mutations: T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion; to a lesser extent, it has shown activity against wild-type EGFR amplifications. The active metabolite AZ7550 has similar potency to osimertinib, while AZ5104 has approximately 8-fold greater potency against exon 19 deletion and T790M mutations and approximately 15-fold greater potency against wild-type EGFR. In vitro, Tagrisso 80mg (Osimertinib) also inhibits HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.Contact us to get your this  drugs in secure way.

Buy Tagrisso 80mg Online Without Prescription. Order Tagrisso 80mg tablets Online. Purchase Tagrisso 80mg Online.

 

Reviews

There are no reviews yet.

Be the first to review “Tagrisso 80mg (Osimertinib) – 30 Tablets pack”

Your email address will not be published. Required fields are marked *